Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.73 |
| ▸ | PRKDC | P78527 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19186610 | 0.84 | F10 (1.00) | F10PRKDCPTGS2KDM1AMAOA | |
| SCHEMBL78438 | 0.83 | SMN1; SMN2 (0.67) | F10PRKDCPOLBKDM1AMAOA | |
| SCHEMBL25207144 | 0.83 | GAA (0.56) | F10PTGS2ALDH1A1MAPT | |
| SCHEMBL78639 | 0.83 | F10 (0.59) | F10POLBKDM1AMAOAMAOB | |
| SCHEMBL12809180 | 0.81 | F10 (0.53) | F10PTGS2 | |
| SCHEMBL4490031 | 0.81 | F10 (0.53) | F10PTGS2 | |
| SCHEMBL1405994 | 0.81 | F10 (0.53) | F10PTGS2 | |
| SCHEMBL15195101 | 0.81 | F10 (0.53) | F10PTGS2NPC1MAPTRAB9A | |
| SCHEMBL15200539 | 0.81 | F10 (0.56) | F10PTGS2NPC1MAPTRAB9A | |
| SCHEMBL118728 | 0.81 | F10 (0.58) | F10PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013120465-A1 | A PROCESS FOR THE PREPARATION OF RIVAROXABAN BASED ON THE USE OF (S)-EPICHLOROHYDRIN | ZENTIVA, K.S. (CZ) | 2013-08-22 | — | — | WO | claimed |
| US-8648189-B2 | Method for the preparation of rivoraxaban | SANDOZ AG (CH) | 2014-02-11 | — | — | US | disclosed |
| US-8648189-B2 | Method for the preparation of rivoraxaban | SANDOZ AG (CH) | 2014-02-11 | — | — | US | disclosed |
| WO-2013120465-A1 | A PROCESS FOR THE PREPARATION OF RIVAROXABAN BASED ON THE USE OF (S)-EPICHLOROHYDRIN | ZENTIVA, K.S. (CZ) | 2013-08-22 | — | — | WO | disclosed |
| WO-2013120465-A1 | A PROCESS FOR THE PREPARATION OF RIVAROXABAN BASED ON THE USE OF (S)-EPICHLOROHYDRIN | ZENTIVA, K.S. (CZ) | 2013-08-22 | — | — | WO | disclosed |
| US-20130184457-A1 | METHOD FOR THE PREPARATION OF RIVORAXABAN | SANDOZ AG (CH) | 2013-07-18 | — | — | US | disclosed |
| US-20130184457-A1 | METHOD FOR THE PREPARATION OF RIVORAXABAN | SANDOZ AG (CH) | 2013-07-18 | — | — | US | disclosed |
| WO-2013105100-A1 | PROCESSES FOR THE PREPARATION OF 5-CHLORO-N-({(5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL)PHENYL]-1,3-OXAZOLIDIN-5-YL}METHYL)-2-THIOPHENE-CARBOXAMIDE AND INTERMEDIATES THEREOF | SYMED LABS LIMITED (IN) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013105100-A1 | PROCESSES FOR THE PREPARATION OF 5-CHLORO-N-({(5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL)PHENYL]-1,3-OXAZOLIDIN-5-YL}METHYL)-2-THIOPHENE-CARBOXAMIDE AND INTERMEDIATES THEREOF | SYMED LABS LIMITED (IN) | 2013-07-18 | — | — | WO | disclosed |
| EP-2521717-B1 | Method for the preparation of rivaroxaban | SANDOZ AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| EP-2521717-A1 | METHOD FOR THE PREPARATION OF RIVAROXABAN | Sandoz AG (CH) | 2012-11-14 | — | — | EP | disclosed |
| EP-2521723-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | Enantia, S.L. (ES) | 2012-11-14 | — | — | EP | disclosed |
| US-20120283434-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | ENANTIA, S.L. (ES) | 2012-11-08 | — | — | US | disclosed |
| US-20120283434-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | ENANTIA, S.L. (ES) | 2012-11-08 | — | — | US | disclosed |
| WO-2011098501-A1 | METHOD FOR THE PREPARATION OF RIVAROXABAN | SANDOZ AG (CH) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011098501-A1 | METHOD FOR THE PREPARATION OF RIVAROXABAN | SANDOZ AG (CH) | 2011-08-18 | — | — | WO | disclosed |
| EP-2354128-A1 | Method for the preparation of rivaroxaban | SANDOZ AG (CH) | 2011-08-10 | — | — | EP | disclosed |
| EP-2354128-A1 | Method for the preparation of rivaroxaban | SANDOZ AG (CH) | 2011-08-10 | — | — | EP | disclosed |
| WO-2011080341-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | ENANTIA, S.L. (ES) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011080341-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | ENANTIA, S.L. (ES) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184457-A1 | METHOD FOR THE PREPARATION OF RIVORAXABAN | VKORC1, VKORC1L1, CYP3A5 | F10 49/4885PRKDC 3733/4885PTGS2 286/4885 |
| US-20120283434-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | F12, VKORC1, CYP2C9 | F10 4/4885PRKDC 4151/4885PTGS2 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.